Breast cancer drug halves cases in high-risk women
A large landmark study funded by Cancer Research UK has found that the breast cancer drug anastrozole can halve the chances of developing the disease in high-risk women.The results of the IBIS II trial, led by Queen Mary University of London and published online in the The Lancet this week, show that in nearly 4,000 post-menopausal women at high risk of breast cancer, taking anastrozole for 5 years cut cases by 53%, compared with a placebo. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 13, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news
Anastrozole may cut breast cancer risk
Conclusion
Overall, the study provides solid and believable evidence that anastrozole can reduce the number of new cases of breast cancer in postmenopausal women at higher than average risk of developing breast cancer.
The study has many strengths, including its large sample size and robust study design. However, the study also has limitations to note.
The results only apply to a specific group of postmenopausal women at a higher than average risk of developing breast cancer. "Higher risk" was defined using a number of very specific criteria. This means the results are not applicable to other groups of postmeno...
Source: NHS News Feed - December 13, 2013 Category: Consumer Health News Tags: Cancer Medication Source Type: news
Anastrozole Halves Breast Cancer Incidence in High-Risk Postmenopausal Women (FREE)
By Amy Orciari Herman
The aromatase inhibitor anastrozole cuts breast cancer incidence in half among high-risk postmenopausal women, according to an industry-supported trial in the Lancet.Nearly 4000 postmenopausal women at increased risk (e.g., … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 13, 2013 Category: Primary Care Source Type: news
Anastrozole Halves Breast Cancers in Prevention StudyAnastrozole Halves Breast Cancers in Prevention Study
Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - December 13, 2013 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Anastrozole reduces breast cancer chance by 53 percent, study says
A new study shows a drug to prevent breast cancer in high risk patients is not only more effective than current treatments, it also comes with far less serious side effects. Vinita Nair reports from New York. (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - December 12, 2013 Category: Consumer Health News Source Type: news
anastrozole could HALVE risk of breast cancer in women with high risk
Taking the drug anastrozole for five years cuts the risk by 53 per cent, say researchers from Queen Mary University of London. (Source: the Mail online | Health)
Source: the Mail online | Health - December 12, 2013 Category: Consumer Health News Source Type: news
Drug Arimidex Cuts Risk for Breast Cancer in Older, High-Risk Women: Study
It could be welcome addition to other preventive meds such as tamoxifen, experts say (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 12, 2013 Category: Cancer & Oncology Authors: webmaster at doctorslounge.com Tags: Gynecology, Oncology, Pharmacy, News, Source Type: news
Morning Break: Arimidex Gets Big Win, Fat Line Flat Lines
(MedPage Today) -- Health news and commentary from around the Web, gathered by the MedPage Today staff. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 12, 2013 Category: Hematology Source Type: news
Drug Arimidex Cuts Risk for Breast Cancer in Older, High-Risk Women
It could be welcome addition to other preventive meds such as tamoxifen, experts say
Source: HealthDay
Related MedlinePlus Pages: Breast Cancer, Medicines (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - December 12, 2013 Category: Consumer Health News Source Type: news
Breast cancer drug 'halves likelihood of high-risk women developing disease'
Anastrozole must be made available on NHS immediately, say charities and authors of trial funded by Cancer Research UKA drug not yet available on the NHS has been found to be better at preventing breast cancer than those approved for use, leading to urgent calls for the National Institute for Health and Care Excellence to make it accessible immediately.The drug anastrozole has been found to halve the likelihood of high-risk women developing the disease and to have fewer side-effects, according to a study published on Thursday in the Lancet medical journal. The Ibis-II study, funded by Cancer Research UK and led by Queen Ma...
Source: Guardian Unlimited Science - December 12, 2013 Category: Science Authors: Alexandra Topping Tags: theguardian.com News Health Society Drugs The National Institute for Health and Care Excellence (Nice) UK news Breast cancer NHS Science Source Type: news
Arimidex Prevents First Breast Cancers (CME/CE)
SAN ANTONIO (MedPage Today) -- Anastrozole (Arimidex) reduced the risk of breast cancer by 53% in high-risk postmenopausal women, a primary prevention trial showed. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 12, 2013 Category: Hematology Source Type: news
Drug Arimidex Cuts Risk for Breast Cancer in Older, High-Risk Women: Study
Title: Drug Arimidex Cuts Risk for Breast Cancer in Older, High-Risk Women: StudyCategory: Health NewsCreated: 12/12/2013 9:35:00 AMLast Editorial Review: 12/12/2013 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - December 12, 2013 Category: Cancer & Oncology Source Type: news
Exercise improves drug-associated joint pain in breast cancer survivors
(American Association for Cancer Research) Breast cancer survivors taking aromatase inhibitors such as anastrozole, letrozole, and exemestane experienced a reduction in joint pain if they exercised while on treatment, according to results presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 12, 2013 Category: Global & Universal Source Type: news
Antihormone therapy anastrozole may provide new option for breast cancer prevention
(American Association for Cancer Research) Breast cancer incidence among postmenopausal women at high risk for developing the disease was significantly reduced by the antihormone therapy anastrozole, indicating that the drug may be an effective new option for breast cancer prevention for this group of women, according to initial results of a double-blind, randomized, placebo-controlled trial presented here at the 2013 San Antonio Breast Cancer Symposium, held Dec. 10-14. The study is being simultaneously published in the The Lancet. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 12, 2013 Category: Global & Universal Source Type: news
Drug cuts breast cancer cases by more than 50 percent in high risk women
(Queen Mary, University of London) Taking the breast cancer drug anastrozole for five years reduced the chances of post-menopausal women at high risk of breast cancer developing the disease by 53 percent compared with women who took a placebo, according to a study published in the Lancet today. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 12, 2013 Category: Global & Universal Source Type: news
